Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 891-903

  Gong, Jiachang ^a   Gan, Jinping ^a   Caceres Cortes, Janet ^a   Christopher, Lisa J ^a   Arora, Vinod ^a   Masson, Eric ^a   Williams, Daphne ^a   Pursley, Janice ^a   Allentoff, Alban ^a   Lago, Michael ^a   Tran, Scott B ^a   Iyer, Ramaswamy A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; BRIVANIB ALANINATE; BRIVANIB ALANINATE C 14; FIBROBLAST GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ALANINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TRIAZINE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG DISPOSITION; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; ANIMAL; BILE; BIOTRANSFORMATION; DRUG ANTAGONISM; FECES; MACACA FASCICULARIS; METABOLISM; NEOPLASM; ORAL DRUG ADMINISTRATION; RADIOASSAY; SPRAGUE DAWLEY RAT; URINE;

ANIMALIA; RATTUS;

ADMINISTRATION, ORAL; ALANINE; ANIMALS; ANTINEOPLASTIC AGENTS; BILE; BIOTRANSFORMATION; FECES; HUMANS; MACACA FASCICULARIS; MALE; NEOPLASMS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79954995887     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037341     Document Type: Article

References (24)

1. Ayers M, Fargnoli J, Lewin A, Wu Q, and Platero JS (2007) Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/ FGFR-1 antagonist. Cancer Res 67:6899-6906. (Pubitemid 47105537)
2. Beaumont K, Webster R, Gardner I, and Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 4:461-485. (Pubitemid 37540382)
3. Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, et al. (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1Hindol- 5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49:2143-2146.
4. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R Sr, Kukral DW, Fura A, et al. (2005) Design, synthesis, and evaluation of orally active 4-(2,4- difluoro-5-(methoxycarbamoyl)phenylamino) pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J Med Chem 48:3991-4008. (Pubitemid 40800608)
5. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, et al. (2008) Discovery of brivanib alaninate ((S)-((R)-1-(4-(4- fluoro-2-methyl-1H-indol-5- yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy) propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 51:1976-1980. (Pubitemid 351438880)
6. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395. (Pubitemid 30208155)
7. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
8. 13C NMR. Steroids 74:250-255.
9. Cross MJ and Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201-207. (Pubitemid 32244307)
10. Ellis LM and Fidler IJ (1996) Angiogenesis and metastasis. Eur J Cancer 32A:2451-2460.
11. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803. (Pubitemid 37328914)
12. Ferrara N, Gerber HP, and LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676. (Pubitemid 36749215)
13. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31.
14. Fung EN, Zheng N, Arnold ME, and Zeng J (2010) Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LC-MS/MS. Bioanalysis 2:733-743.
15. Gerwins P, Sköldenberg E, and Claesson-Welsh L (2000) Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 34:185-194. (Pubitemid 30320963)
16. Hazenberg MP, de Herder WW, and Visser TJ (1988) Hydrolysis of iodothyronine conjugates by intestinal bacteria. FEMS Microbiol Rev 4:9-16. (Pubitemid 18267351)
17. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
18. Klagsbrun M and Moses MA (1999) Molecular angiogenesis. Chem Biol 6:R217-R224. (Pubitemid 29380763)
19. Klebl BM and Müller G (2005) Second-generation kinase inhibitors. Expert Opin Ther Targets 9:975-993. (Pubitemid 41488835)
20. Manetti F and Botta M (2003) Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK). Curr Pharma Design 9:567-581. (Pubitemid 36221724)
21. Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, and Fargnoli J (2009) Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 65:55-66.
22. Mekhail T, Masson E, Fischer BS, Gong J, Iyer R, Gan J, Pursley J, Patricia D, Williams D, and Ganapathi R (2010) Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. Drug Metab Dispos 38:1962-1966.
23. Roberts MS, Magnusson BM, Burczynski FJ, and Weiss M (2002) Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790. (Pubitemid 34948196)
24. Tassi E and Wellstein A (2006) Tumor angiogenesis: Initiation and targeting- therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas. Cancer Res Treat 38:189-197.